On average, completers achieved 11.5% weight loss vs 7.3% for placebo at 56 weeks 1,3,5 ITT-LOCF: 8.1% weight loss for CONTRAVE and 4.9% for placebo 1 Completers lost an average of 25 lb vs 16 lb for placebo at 56 weeks 5 ITT-LOCF: ~18 lb for CONTRAVE and ~11 lb for placebo 1 There was an average decrease of 4.4 inches in waist circumference for completers vs 3.0 inches for placebo 6 ITT-LOCF: Decrease of 3.9 inches for CONTRAVE and 2.7 inches for placebo 1 In another randomized controlled trial (COR-I) with similar average baseline parameters to those for COR-BMOD, endpoint results over 56 weeks in completers/ITT groups for patients taking CONTRAVE (n=296/538) vs placebo (n=290/536), respectively, were mean weight change from baseline (8.1%/5.4% decrease vs 1.8%/1.3%), patients achieving 5% weight loss (62%/42% vs 23%/17%), and mean change in waist circumference (2.7-inch/2.4-inch decrease vs 1.0 inch/1.0 inch)
8 AM - 5 PMP: 619-825-3835 *City residents only
Possible Side Effects Nausea Vomiting Diarrhea Constipation Stomach pain or discomfort Decreased appetite Indigestion or gas Redness, itching, or soreness at the injection site Most side effects are mild to moderate and may improve as your body adjusts to treatment
3094 In Re: GLP-1 Receptor Agonists Products Liability Litigation , currently pending in the Eastern District of Pennsylvania
